메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

NX Taiwan Awarded Healthy Workplace Certification by "Ministry of Health and Welfare"

[ 메디채널 김갑성 기자 ] - Received High Praise for Promoting Health Management and Contributing to Local Communities - TOKYO, Aug. 4, 2025 -- Nippon Express (Taiwan) Co., Ltd. (hereinafter "NX Taiwan"), a group company of NIPPON EXPRESS HOLDINGS, INC., has been accorded Healthy Workplace Certification by the Health Promotion Administration (HPA) of "Taiwan's Ministry of Health and Welfare" in recognition of the company's commitment to creating sustainable workplaces that emphasize the health and welfare of employees. Logo: https://drive.google.com/file/d/1dqm0cxpYa
- 김갑성 기자
- 2025-08-04 15:00
Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer

TAIPEI, Aug. 4, 2025 -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). This open-label, multi-center international study plans to enroll 66 patients with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC to evaluate the safety and preliminary efficacy of the triplet therapy. Enroll
- 김갑성 기자
- 2025-08-04 14:37
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 3, 2025 -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, a leading ophthalmic research institution in China. The trial was conducted by Professor Ying Jie, Director of the Ophthalmology Center,
- 김갑성 기자
- 2025-08-04 14:29
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease

BEIJING, Aug. 4, 2025 -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canaliculus plug for the treatment of dry eye disease (DED). The milestone was achieved at Beijing Tongren Hospital, Capital Medical University, a leading ophthalmic research institution in China. Unmet Needs in DED Management Dry eye is a multifactorial ocular surface disease. Management of DED is oft
- 김갑성 기자
- 2025-08-04 14:05
Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

HONG KONG, Aug. 4, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by both China's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezoliz
- 김갑성 기자
- 2025-08-04 13:56
CAS SciFinder integrates transformative new science-smart AI capabilities to enhance R&D efficiency and boost innovation

Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery COLUMBUS, Ohio, Aug. 4, 2025 -- CAS, a division of the American Chemical Society specializing in scientific knowledge management, announces the launch of the next evolution of CAS SciFinder®, the leading scientific search and insights platform. By integrating advanced AI—optimized for scientific applications—with the largest human-curated collection of global scientific knowledge, CAS SciFinder empowers researchers across R&D to work faster and unlock new opportuni
- 김갑성 기자
- 2025-08-04 12:01
CAS SciFinder, 혁신 과학지능형 AI 기능 통합으로 연구개발 효율성 제고 및 혁신 촉진

선도적인 솔루션으로 과학자에게 더 빠른 실행가능한 답변을 제공해 과학적 발견 가속화 콜럼버스, 오하이오 , 2025년 8월 4일 -- 미국화학회(American Chemical Society)의 과학 지식 관리 부문인 CAS가 과학검색•인사이트 플랫폼의 선두주자인 CAS SciFinder®의 차세대 버전 출시를 발표했다. CAS SciFinder는 과학 응용 분야에 최적화된 고급 AI를 사람이 엄선한 세계 최대 규모의 과학 지식 컬렉션과 통합해 연구자들이 더 빠르게 작업하고 새로운 혁신 기회를 발굴할 수 있도록 지원한다. 이는 CAS 솔루션 포트폴리오 사상 가장 중요한 AI 통합이다. 팀 발버그(Tim Wahlberg) CAS 최고제품책임자(CPO)는 "과학 정보는 너무도 다양하고 복잡해 일반적인 AI 도구가 정확히 해석하기 어렵다"면서 "CAS Content Collection™의 고품질 정형 데이터에 이러한 기술을 적용하고 당사의 과학자들을 통해 고급 AI 모델을 검증함으로써 과학자들이 신뢰할 수 있는 정확한 답변을 제공하는 과학지능형 AI 접근방식을 개발하는 데 성공했다"
- 김갑성 기자
- 2025-08-04 12:01
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a first-in-human (FIH) clinical study of JSKN022 for the treatment of advanced malignant solid tumors. JSKN022 is an innovative bispecific ADC developed in-house with Alphamab's
- 김갑성 기자
- 2025-08-04 09:28
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics

Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 -- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation.&nb
- 김갑성 기자
- 2025-08-04 08:00
United Imaging Teases Multi-modality "Provider Success" Product Launches at AHRA 2025

The newly FDA-cleared uMR® Ultra and the uOmniscan™ are the first major announcements leading into the AHRA Annual Meeting in Las Vegas. HOUSTON, Aug. 4, 2025 -- United Imaging, a global manufacturer of modern medical imaging technology, will again be among the largest exhibitors at AHRA 2025 in Las Vegas, the Association for Medical Imaging Management, with a very hands-on, interactive display of new software and hardware technology. Building on examples of how it helps healthcare providers be successful, the company will showcase its breadth and scale across 85 countries (
- 김갑성 기자
- 2025-08-04 00:22

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-08-31_SUN

마이디어 그룹, 2025년 상반기 사상 최고 실적 달성 03:54

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 05시 20분